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ABSTRACT
Dystrophia myotonica (DM1), one of the most common forms of muscular dystrophy, is caused by a
repeated trinucleotide expansion in the DMPK gene. This mutation results in the accumulation of toxic
cellular RNA transcripts. Spliceosome-mediated RNA trans-splicing (SMaRT) technology is a form of
gene therapy that possesses the potential to correct these toxic RNA transcripts and thus cure the disease.
Despite its promise, prior applications of SMaRT technology to DM1 have been hampered by poor
efficiency and have not been validated in a relevant model of the disease. In order to improve the
efficiency of trans-splicing, this study examined the use of novel SMaRT molecules containing altered
binding domains. These SMaRT molecules were tested in a clinically relevant cell model of DM1 and
their corrective ability compared to that of a standard SMaRT molecule. The results were quantified by
RT-PCR. The outcome of this study indicated the need to utilize more specific methods for measuring
efficiency and for understanding the specific interactions of SMaRT molecules with target transcripts.

INTRODUCTION
1. DM1 overview
The foundation set in the mid-20th century regarding the molecular basis of heredity resulted in a new
perspective into disease etiology and pathology. With the completion of the human genome project and
the systematic mapping of genes in the early parts of the 21st century, many disease states could, for the
first time, be linked to genetic mutations. The result was the re-categorization and diagnosis of disease
2

from a system based largely on symptoms and physical manifestations to one more closely defined by
molecular signatures.
1.1 Physical Characteristics associated with Dystrophia Myotonica Type 1
Myotonic Dystrophy or dystrophia myotonica type 1 (DM1) stands as an archetypal example of a disease
whose identity has been re-examined and redefined in the genetic era. DM1 ranks as one of the most
common types of muscular dystrophy and is considered the highest overall contributor to adult muscular
dystrophies. It is estimated that as many as 20 in 100,000 people are affected by DM1 1 . The
characteristics associated with the syndrome were first identified in the early 1900s by the German
physician Hans Steinert2. Because of his work, this type of muscular dystrophy was first referred to as
“Steinert’s disease”. Some of the prominent physical manifestations that are characteristic to DM1
include muscle weakness and wasting, myotonia, cardiovascular disorders and cataracts3.
1.2 Genetic Description
With the rise of genetic testing, a specific genetic anomaly was identified with DM1. Through patient
testing, it was found that the symptoms of DM1 were associated with an extended trinucleotide repeat
(CTG) within the dystrophia myotonica protein kinase (DMPK) gene. The repeat sequence is located
within the 3’ untranslated region of exon 15.

This repeat sequence is present within all DMPK

transcripts and within a phenotypically normal individual it contains up to 50 repeats4. Through a
process called repeat expansion, additional CTG repeats can be added during the replication preceding
meiosis, allowing the repeat section to be increased. The result is that in subsequent generations these
repeats can accumulate causing the repeat expansion to become increasingly enlarged. Individuals with
fewer than 37 repeats are considered to be free from the risk of affected offspring5. The expansion size
can range anywhere from hundreds to thousands of repeats. The severity of the disease, however,
increases as the numbers of repeats increases. Alleles containing more than 1000 repeats are responsible
for the most severe form of the disease, congenital onset DM1, which carries an increased mortality
rate6. Table 1 gives a succinct listing of the interaction between trinucleotide expansion length and
disease expression patterns as defined by the NCBI7.
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Table 1: CTG repeat length and DM1 expression8

by nucleotide repeat expansions. As part of

(CUG)n
Repeat Size (n)
35 - 49
50 - ~150
~100 - ~ 1000
> 1000

DM1 is one of a number of diseases caused

Classification
Normal
Mild DM1
Classic DM1
Congenital

Age of Onset
N/A
20-70 years
10-30 years
Birth-10 years

this class of diseases, DM1 takes its place
among

spinocerebellar

ataxias

(SCA),

fragile-x syndrome (FXS), Freidrich ataxia
(FRDA), as well as Huntington disease
(HD)9, 10

2. Proposed toxicity mechanisms within DM1: A multi-faceted disease
Knowing the particular genetic mutation associated with a disease state is only the beginning of a full
understanding that could lead to practical cures. Following the initial identification of the genetic
mutation associated with DM1, much of the research focused on nucleotide repeat disorders has
involved determining the molecular mechanisms that lead to the symptoms observed in the disease state.
DM1 has proved to be one of the prime models used to study the mechanisms of toxicity of genes bearing
expanded repeats. Though some pieces are coming together, the full picture of the mechanisms of
pathogenesis of DM1 still remains muddled and inexact. In the quest to discover what is occurring
within the cells containing the extended repeat, many mechanisms have been hypothesized and
investigated.
2.1 Protein Toxicity
Although DMPK expression by the expended repeat may not be affected, the portion of the 3’
untranslated region of the DMPK gene which contains the CTG repeats is overlapped by the promoter
for another gene, the sine oculis related homeobox 5 (SIX5) gene11. Within cells that contain mutant
DMPK genes, there is an indication that SIX5 transcription is impaired. As evidence of this, knockout
murine models displayed the occurrence of ocular cataracts, a characteristic of DM1. Because of this
result, it is thought that loss of SIX5 may play a role in part of the observable symptoms associated with
the disease12.
Recent studies have also identified the potential for the production of a harmful protein product from
the extended repeat sequence through a mechanism called Repeat Associated Non-ATG translation
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(RAN translation)13. Within expanded CAG sequences, translation has been found to occur through nonATG-initiation mechanisms.

Though the DMPK gene is transcribed in the sense direction, the

occurrence of bidirectional transcription has been observed in similar expanded trinucleotide repeat
diseases such as Huntington disease-like 2 (HDL2), spinocerebellar ataxia type 8 (SCA8), and fragilex ataxia syndrome (FXTAS)14. This bidirectional transcription within mutant DMPK genes would result
in transcripts comprised of elongated CAG and CUG sequences capable of RAN translation. When
RAN occurs in DM1 transcripts, the reading frame is arranged in all three windows on both transcripts,
resulting in five different theoretical long homomeric protein chains: polyglutamine, polyserine,
polyalanine, polyleucine, and polycysteine15. Within murine neuroblastoma cells, it was found that the
presence of these long homomeric protein chains was associated with cellular apoptosis16. This newly
investigated mechanism holds much potential in understanding the molecular pathogenesis of DM1 and
may be an important cause of DM1 symptoms.
2.2 RNA Toxicity
The main focus of DM1 toxicity, however, has been on the role of the mutant RNA transcripts within
the disease pathway. The idea of RNA toxicity is based on RNA-gain of function. Gain of function
occurs when any molecule assumes a mechanism or action that it does not normally perform. Mutant
RNA is particularly susceptible to picking up new functions due to its ability to form diverse secondary
structures and its known place in cellular regulation. The precise processes of RNA pathogenesis are
areas of much intense research, but three prime mechanisms of RNA sabotage have come into focus:
the sequestration of MBNL1, the foci formation of the MBNL1 and mutant DMPK complex, and the
overexpression of CUGBP1.
MBNL1 is a member of the musclebind family of proteins and is responsible for the regulation of
alternative splicing of specific genes, including the pre-mRNA of the chloride channel (CLCN1), insulin
receptor (IR) and cardiac troponin-T (TNNT2) genes.17, 18 The presence of extended CTG repeat results
in the binding of the MBNL1 to the mutant DMPK RNA19, which recognizes the double stranded hairpin
structures formed by the CUG repeats20. The MBNL1 and mutant DMPK complex is proposed to affect
the cell in two ways. The first and simplest consequence comes from the loss of function of MBNL1.
13
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Because of the exclusive binding that occurs between MBNL1 and the mutant DMPK, it is proposed
that this sequestration results in MBNL1 being unavailable for the regulation of splicing for which it is
responsible21. With the mutant DMPK-induced loss of function of MBNL1, a high rate of aberrant
splicing is observed among cellular transcripts, many of which are linked directly to phenotypic
manifestations of DM122. As evidence of this, transgenic mice containing non-binding MBNL1, display
abnormalities and defects that are consistent with those observed in DM1, in particular, the occurrence
of myotonia, ocular cataracts and aberrant splicing patterns23.
CUGBP is another important RNA binding that has been implicated in the molecular pathogenesis of
DM1. Like MBNL1, CUGBP is integral to splicing pattern determination and the two proteins work in
concert to regulate splicing patterns24. CUGBP has also been identified as being important in mediating
mRNA decay and increasing translation of proteins such as p2125,26. When MBNL1 concentrations are
disturbed by the formation of the mutant DMPK-MBNL1 complex and its segregation to the nucleus,
CUGBP levels are increased. The abnormal ratio of these two proteins with DM1 cells is similar to that
in the embryonic state27.
The loss of MBNL1 and CUGBP1 function has been shown to be only a partial contributor to DM1
pathogenesis. Studies point to the MBNL1 and mutant DMPK complexes being integral to the
development of the DM1 phenotype. Within DM1 cells, the MBNL1-mutant DMPK complexes form
foci which are localized in the nucleus. Though healthy cells do not typically display these foci, it was
found that the position of these complexes in the nucleus rather than in the cytoplasm was key to DM1
toxicity. Why cytoplasmic foci would not display the same toxicity as nuclear foci is not known, but it
gives an important indication that part of the toxicity caused by these complexes must involve
interference with the normal processes of the nucleus28, 29. It should also be noted that both CAG and
CUG repeats have been found to equally contribute in foci formation30. These foci are increasingly
becoming the most strongly associated mechanism with the pathogenesis of DM1. A summary of
proposed mechanisms can be seen in table 2.
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Table 2: Proposed Mechanisms of Toxicity within DM1
Protein
Type

DMPK
protein loss

RAN
translation

SIX5 gene
expression
disruption

Category

DM1
Phenotypes
Associated
Late onset
myopathy;
delays in
cardiac
conduction

Description

Result

Mutant DMPK
transcripts interfere
with normal
translation
processes

Decreased levels of
DMPK protein

Gain of
function

Random non ATG
initiated translation
occurs

Homopolymeric
polyglutamine,
polyalanine and
polyserine proteins
created which can
interfere with
cellular processes

Still under
investigation

Cleary,
Ranum,
2014; Zu et
al 2010

Decreased
expression

Overlap of DMPK
UTR with promoter
of SIX5 gene

Extended repeats in
DMPK may inhibit
or limit expression
of the SIX5 protein

Ocular
cataracts

Flippova,
et al, 2001

Binding of MBNL1
to DMPK transcripts
results in MBNL1
not being available
for splicing
regulation of normal
target proteins

Myotonia,
ocular
cataracts,
cardiac
conduction
defects

Sicot et al,
2013;
Kanadia et
al, 2003

Loss of
function

Sources
Jansen, et
al, 2003;
Berul et al,
1998

RNA

MBNL1
sequestration

Loss of
function

MBNL1 associates
with extended
repeat portion of
mutant DMPK

MBNL1DMPK
nuclear foci
formation

Gain of
Function/inter
ruption of
baseline

MBNL1 complexes
with mutant DMPK
and forms foci
within nucleus

Foci seem to be
toxic when located
within the nucleus

Still under
investigation

Mankodi et
al, 2001;
Taneja et
al, 1995

Overexpression

CELF expression
associated with
MBNL1, loss of
MBNL1 results in
increased
expression of
CUGBP

Missplicing of
targeted transcripts
including Tnnt2,
Mtmr, Clcn1; return
to fetal splicing
patterns;
Insulin resistance

Myotonia,
muscle
wasting,
DM1
histopathy,

Ho et al,
2005; Ward
et al, 2010;
Timchenko
et al, 2001;
Philips et
al, 1998

CUGBP1
(CELF)
upregulation
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3. Methods of Repair of DM1
The understanding of disease processes is driven by the quest to find methods of alleviation and
treatment. Increased genetic classification and identification of diseases has given rise to new forms of
treatment. Targeting molecular sources of disease is all part of the increasingly prominent field of gene
therapy. Traditional gene therapy approaches have mainly focused on introducing complete genes in
order to restore proper protein levels within a system. Though this aspect may relieve some symptoms,
the previous discussion on mechanisms of disease shows that in a DM1 individual the main pathogenesis
is due to the presence of mutant DMPK RNA. Because of this, molecular therapeutic treatments for
DM1 must include targeting of these toxic RNA transcripts. Ideally, molecular therapy for correction
of DM1 would fulfill all of the following requirements. 1) Therapy mechanism would be specific to
mutant DMPK transcripts only. 2) Therapy molecules would be small enough to effectively administer.
3) Therapy would retain the normal transcription levels dictated by the cell and would not interfere with
cellular control mechanisms.
Several strategies of targeting extended repeat DMPK transcripts have been proposed to treat DM1. The
use of small interfering RNA (siRNA) has been proposed and tested as a possible mechanism for mutant
DMPK RNA repair. SiRNA are small double stranded RNA molecules homologous to an intended
target. These molecules have been shown to bind to target RNA and induce post transcriptional
silencing through targeting of mRNA for degradation by endogenous enzymes. Within a DM1 model,
siRNA modified for nuclear localization were shown to successfully degrade nuclear and cytoplasmic
DMPK transcripts. The difficulty arising from this method of DM1 alleviation, however, was the failure
of the mechanism to distinguish between the mutant and wild-type DMPK transcripts31. Additionally,
the destruction of DMPK transcripts that occurs in this therapy greatly alters the steady cellular levels
of DMPK protein being translated, an event which usually has severe consequences to the cell.
A more promising method is to be found in the family of antisense oligonucleotides (AONs).

Two

leading classes of these AONs have been used with DM1, 2’O-methyl-modified AONs (MOEs) and
phosphodiamidate morpholino antisense molecules (PMOs or morpholinos)32. Similar to the use of
siRNA, AONs work by post transcriptional gene silencing, either by targeted degradation or by steric
interference induced inhibition. Certain MOEs have been tested within a DM1 cell model, and it was
found that this therapy model appeared to effectively degrade and reduce the number of mutant DMPK
mRNA within both the cytoplasm and the nucleus. In vivo trials showed up to 80% silencing of the
31
32
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expanded repeat DMPK transcripts33. A study has also shown morpholinos successful in disrupting the
mutant DMPK mRNA and MBNL1 foci within the nucleus. There was also some indication that the
morpholinos might increase the degradation of these transcripts34. In both cases, however design of
these AONs was only theorized to be specific to extended CUG repeats.

Whether normal DMPK

transcripts were also affected was not thoroughly evaluated, though in general the specificity of
morpholinos has been shown to be fairly high35. Though the use of AONs holds the possibility of
disrupting the toxic DMPK foci, as with the previously discussed RNA interference pathways, these
therapies fall short of the ideal in their inability to retain the normal DMPK expression patterns that
occur when both DMPK alleles are producing functional mRNA.
Answering the call of this short-coming, a new area of gene therapy has risen and begun to take its place:
mRNA repair through the use of trans-splicing.

Eukaryotic mRNAs require post-transcriptional

modification which includes the splicing together of exons and the removal of introns. The splicing
normally observed in this stage is referred to as cis splicing, and occurs within a single linear pre-mRNA
molecule. The arrangement of exons and
exclusion of different areas of the molecule is
in part responsible for the great variation seen
in eukaryotic organisms.

Trans-splicing

works similarly, however, the splicing in this
instance is no longer within the same
molecule, but occurs between two different
pieces of RNA.

Figure 1 gives a visual

example of the difference between the two
methods of splicing.
As can be seen in the figure, trans-splicing allows the substitution of another portion of RNA within a
modified mRNA transcript. The application to genetic therapy is readily apparent. Different from the
methods previously mentioned, trans-splicing could potentially repair mutant transcripts prior to
translation and without modification or alteration of the promotion or transcription of the gene. Within
DM1, trans-splicing would allow the mutant exon 15, containing the extended trinucleotide repeat, to
be replaced with a normal exon 15, containing fewer than 50 repeats.

33
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The therapeutic use of trans-splicing was first explored with the use of ribozyme-mediated transsplicing. This type of trans-splicing repair makes use of a synthetically arranged sequence containing
both a binding domain for locating of the target RNA, and the exonic sequences to be spliced. In order
for splicing to occur within this model, however, a RNA catalyst, or ribozyme must also be included
within the therapeutic molecule. Past studies have examined the repair characteristics of this method of
therapy in several disorders including their repair efficiency in DM1 fibroblast cells 36. Though repair
has been observed using such mechanisms, ribozyme mediated trans-splicing has several shortcomings
which prevent its progression to a clinically relevant therapy option. The most prominent of these are
linked to the necessary inclusion of the ribozyme. The main difficulty faced with this approach was the
inefficiency of the included ribozyme within physiological Mg+ concentrations37.
In 1992, it was discovered that mammalian cells possessed the endogenous machinery necessary for
performing trans-splicing38. This revelation opened a new opportunity for the use of trans-splicing.
Within the mammalian cell, the enzyme responsible for splicing is the spliceosome. Based on the
finding that eukaryotic spliceosomes were capable of performing trans-splicing as well as the usually
observed cis-splicing, a novel method of RNA repair was introduced: spliceosome mediated transsplicing (SMaRT). Since all eukaryotic cells contain the spliceosome needed for SMaRT technology,
the need to supply machinery such as ribozymes for initiating the splicing event was obviated. Since
the strongest setbacks in feasibility of use of trans-splicing for therapy were due to presence of the
ribozymes, SMaRT has become a much more promising type of RNA repair.
Since its introduction, the mRNA repair capabilities of SMaRT therapy have been examined in a
growing number of genetic disorders. Artificial trans-splicing has been conducted in disease models of
hypertrophic cardiomyopathy 39 , Huntington’s disease (HD) 40 , epidermolysis bullosa simplex with
muscular dystrophy (EBS-MD)41, and hemophilia A42. This type of trans-splicing was also used within
the context of DM1 by Chen et al in 2009. Most of these studies have served as proof of concept for
SMaRT mRNA repair.
The translational potential of SMaRT technology is difficult to judge due to several reasons. One reason
is due to the wide variability in efficiency measurements which prevents direct comparison. Several in
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vitro experiments have reported trans-splicing efficiency between 1-14%. In vivo studies, however, the
efficiency has been found between 3-7%43. In a study where SMaRT was applied directly to DM1, the
efficiency of repair was 1.8-7.41%44.
Additionally, the differences in disease models also effects the conclusions as to the efficiency of the
SMaRT therapy. Many of the disease models used thus far have been made by the use of artificial
constructs, where the desired target of repair is found within an extra-chromosomal plasmid. For some
of the genetic mutations, such as HD and EBS-MD, the trans-splicing evaluation of the PTMs was also
evaluated within patient-derived cell lines endogenously containing the mutated alleles4546. In general,
the trans-splicing efficiency was greatly decreased within most of the more clinically relevant
conditions. The efficiency of splicing repair in these studies was much less than in the artificial
constructs.
Despite the diversity of these studies, a common theme has been emphasized: the need for more
efficiency and specificity of the splicing events. For diseases where loss of protein is the main influence
in disease prognosis, small levels of trans-splicing repair may be sufficient to alleviate symptoms.
Because if this, PTMs with low splicing efficiency may be satisfactory. It is important to note however,
that low levels of trans-splicing repair may be enough to alleviate the disease state. Even with the low
efficiency of current SMaRT technology, research using murine disease models have shown the
technology capable of causing significant phenotypic changes in hemophilia A and hypertrophic
cardiomyopathy4748.
For DM1, however, the presence of mutant mRNA is the main source of toxicity. It is not known how
many mutated DMPK transcripts are required for toxicity to occur. Thus it can be assumed that DM1
will require much higher trans-splining efficiency due to the RNA toxicity nature of the disease. Before
SMaRT can become a feasible clinical therapy option for patients suffering from DM1, it is imperative
that the splicing efficiency of the therapeutic PTMs be improved. Additionally, a clinically relevant
model of DM1 has not yet been used to evaluate SMaRT technology. Since the efficiency of transsplicing is not adequately reflected in artificial disease constructs, any improvement in efficiency must
be evaluated within a model that reflects the complexity of the actual disease state.
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4. Experimental Details
The purpose of this study was to improve PTM efficiency and specificity and to examine the transsplicing repair of PTMs using a patient-derived DM1 cell. Because SMaRT technology relies on
endogenous cellular mechanisms for splicing, the key to improving trans-splicing efficiency is to
improve the PTM design so that it can be correctly identified by the cell and positioned near the desired
target transcript. Understanding how to improve PTM efficiency requires knowledge of PTM design as
well as an understanding of how genetic material is naturally positioned and associated within the
nucleus.
4.1 Experimental Theory
Basic PTMs are comprised of
several specific sequences that
fall into three main categories
based on their function: the
binding domain, the splicing
domain, and the coding domain49.
Each serves an important function
within the cell and are visually
represented in figure 2.

The coding domain contains the portion of RNA that is to be incorporated into the target transcript. The
splicing domain consists of several unique features, most importantly, the pyrimidine-rich tract, the
3’splice site and the branch point. These are all features which allow the spliceosome machinery to
identify this molecule as a splicing candidate and to correctly associate with it. Typically, the splicing
domain portions of the PTM are analogous to the splicing factors that would be found within an
endogenous intron. The final sequence of interest is the binding domain. The purpose of the binding
domain is to provide a sequence which will cause the cell to position the PTM near its target gene.
Because splicing occurs co-transcriptionally, it is necessary that the PTM be located near to the actively
transcribed target gene. It is this portion which largely determines the molecule’s specificity and
efficiency. The best PTM design is one which contains a binding domain that has learned to speak the
language of nuclear positioning and sends a clear address of destination.

49
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Since the goal is to localize the PTM to the position in the nucleus where transcription of the desired
target is occurring, an understanding of nuclear organization is necessary. The idea that the nucleus is
a random network of genes and proteins has long been refuted and it is now known that the structure of
its interior is highly complex. Where genetic material is positioned within the nuclear matter is closely
linked to the regulation of gene expression. It has been found that within the nucleus, transcription
tends to occur within foci, or in distinct groupings commonly referred to as transcription factories. These
transcription factories contain several genes which are actively transcribed by RNA polymerase II50.
What is of importance is how the grouping of genes are determined within the factories. To date, this
area currently under investigation, however it has been shown that homology of genes is a strong
influence in the grouping seen in these foci51. This concept was promoted by the finding that when a
plasmid containing a β-globin gene was introduced to a mammalian cell, the nuclear machinery
colocalized the plasmid with the homologous endogenous gene52. Other studies have indicated that the
promoter region of the gene may be the sequence responsible for inclusion in the transcription factory,
that is, that homologous promoters are sequestered into the nuclear foci53.
In order for a PTM to be efficiently transcribed and trans-spliced into the correct target, it must be
located within the same transcription factory as the gene of interest. Traditionally, the binding domain
of PTMs has consisted of a sequence that is antisense to an intronic portion of the targeted pre-mRNA.
This design is founded on the idea that the main stimulus in nuclear positioning is canonical WatsonCrick base pair complementarity. The recent investigations into the organization of the nucleus and the
transcription factories cited above challenge this assumption. Based on the previously stated study
regarding plasmid positioning within the genome, there is strong evidence that homology rather than
complementarity may provide the strongest nuclear positioning “address”.

Because of this it is

proposed that using a PTM containing a binding domain homologous to the target will increase the
efficiency of trans-splicing.
Experimental Design
In this experiment, PTMs containing binding domains which were homologous to intron 14 of the
DMPK gene were created. The efficiency of these molecules was compared with that of PTMs
containing the traditional antisense binding domain. The efficiency of the two was evaluated by the use
of two control PTMs. For each of the experimental PTM types, controls were created by alteration of
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the 3’ splice site needed for recognition of the spliceosome. Figure 3 shows the four experimental PTMs
created for the experiment. An overall control was also used where no PTM was added to the cell
culture.
The

model

used

for

this

experiment was a GM23300
lymphocyte cell line derived
from a patient suffering from
DM1 and acquired from Coriell
repositories.

This cell line

contained both a mutant DMPK
allele with around 150 to 160
CTG repeats present in the
mutant gene as well as normal allele. The large difference in size between the wild type and the toxic
DMPK transcript allows the two to be separated by size. Thus, when run on a gel, a sample containing
both types of transcripts would be expected to show a high band around 990 bp and a low band around
500 bp.
Evaluation of the presence of mutant DMPK transcripts by band density was the method employed for
this experiment. The density of the high band within the gel indicates the amount of toxic transcripts.
Because a normal wild-type transcript is already present within the cell, the low band contains both
trans-spliced correct DMPK mRNA as well as the normal transcripts derived from the endogenous wildtype allele and prevents the direct determination of repaired transcripts. However, as the efficiency of
PTMs increases, the density of the high band should decrease and the low band increase. Using this
ratio of the two bands, the efficiency of the PTMs of interest can still be determined. To standardize the
expression levels between samples the amount of the housekeeping gene GAPDH was quantified.

METHODS AND MATERIALS
1. Designing PTMs
1.1 Replication of normal intron 14 and exon 15
A cell line containing two normal DMPK alleles (<50 CTG repeats) was used to isolate the coding
domain for the PTMs. The DNA from these cells was gathered using DNeasy DNA extraction kit from
Qiagen. PCR was performed with the extracted DNA as template using forward and reverse PCR
14

Primers, DMPK P1 and DMPK P2. These primers were designed to amplify the portion of the gene
containing intron 14 and exon 15. Table 3 provides a tabulated compilation of all primers used in the
experiment. An inserted CACC sequence was added at the beginning of the forward primer, DMPK P1
to allow for insertion into the TOPO vector. AcuPrime GC Rich DNA polymerase was used due to the
high CG content of the desired sequence.
The PCR reaction was performed using 200 ng of template DNA. The resulting product was run on a
0.5% agarose gel alongside a 1 kb ladder. A visible band appeared within the range of the expected size
for the PCR product, which was approximately 1356 bp. The portion of the gel containing this product
was excised and the genetic material removed from the agarose with a gel extraction kit.
1.2 Creation of sense PTM plasmids: pc3.3 DMPK
Using the pc.DNA3.1 Directional TOPO Expression kit from Invitrogen, the PCR product was ligated
into the backbone according to the manufacturer’s protocol. These plasmids were introduced into
chemically competent TOP10 bacterial cells via heat shock, plated on a pre-warmed plate containing
ampicillin and allowed to grow overnight. It was observed that the growth of these colonies was much
slower than to be expected.
Three colonies were chosen from the plate and the plasmids were extracted using Qiagen’s MiniPrep
kit. To confirm the presence of the DMPK portion within the cellular plasmids, the collected genetic
product from the three cell lines were treated
with Nde I and XhoI restriction enzymes. After
separating the fragments by gel electrophoresis,
the second sample was the only one to show a
band within the proper range for the desired
product.

This clone was submitted for

sequencing which confirmed that the topo
plasmid contained the amplified intron 14 and
exon 15.
Further modifications were made to the inserted
DMPK portion. Using site directed mutagenesis the 5’ GT splice site was removed to prevent any cissplicing from occurring within the molecule. An EcoRI site was also added just upstream of exon 15.
An image of the modified pcDNA plasmid can be seen in figure 4.
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Table 3: PCR Primers
Sequence (5’ 3’)
DMPK P1
DMPK P2
DMPK3ss_for

Forward
CACCTACGTCCGGCCCAG G

TAGCTCCCAGACCTTCG
CGCCCTCTCCCGCACGTCCCTA
GGC
GCCAGGCCTAGGGACGTGCGGGGAG

DMPK3ss_rev
DMPKin14 P1

AACTTGGTACCCCCGGCATGG
GCCT
TCAACAGAATTCGAGCTCGGATCCAGT

DMPKin14 P2
DMPK RT 3
DMPK RT 4

Reverse

CGGATCCTTCCCATCTA
CTGGCCGAAAGAAAGAAATG

1.3 Creation of anti-sense binding domain PTM: pc 3.3 DMPK AS
To create an anti-sense sequence, the binding domain was amplified by PCR using primers DMPKin14
P1 and 2. These were designed to introduce a KpnI restriction site at the end of the binding domain of
intron 14 and an EcoRI restriction site upstream of the donor splice site. Sense PTM plasmids and the
purified PCR product from this step were both digested with KpnI and EcoRI and then ligated together.
Because of the location of the KpnI and EcoRI within the vector, this step reversed the orientation of
the binding domain portion, resulting in the desired anti-sense PTM.
1.4 Creation of control PTM plasmids: pc3.3 DMPK 3’ss and DMPK AS 3’ss
Controls were created for both the DMPK and DMPK AS PTMs by alteration of the AG 3’ acceptor
splice site. Through site directed mutagenesis, the AG splice site within intron 14 was replaced with a
theoretically, inoperable AC sequence. This step was performed by the use of primers DMPK 3ss_for
and 3ss_rev.

2. Optimization of analysis conditions
2.1. Optimization of PCR reaction
The GM23300 cell-line was the model used for this experiment. Prior to any experimentation, the
baseline parameters of the experimental conditions were determined by optimization of RNA extraction,
RT-PCR and electrophoresis conditions.
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Total mRNA from the DM1 cells was extracted using RNeasy mini kit from Qiagen. This mRNA
product was subjected to RT-PCR with using primers DMPK RT P3 and P4. These primers were
specialized to amplify the portions of transcript that included both the exon 14-15 junction and the
(CTG)n repeat in Exon 15. Transcripts from the mutant allele were expected to be around 884-914 base
pairs with the normal allele expressing mRNA of only 494 bp in length. These two transcripts were
visibly distinguishable when run on a 0.5% agarose gel.
Initially, some trouble was met in the PCR reaction particularly in the amplification of the mutant DMPK
transcripts due to the high GC content. This difficulty was removed by the use of 5% DMSO in the PCR
reaction mixture. The resulting optimized PCR mixture and conditions for the DMPK replication is
listed in Table 4.

GAPDH was used as the housekeeping gene. The PCR reaction analysis of this

product was also adjusted prior to experimentation. Table 5 gives the subsequent settings for RT-PCR
of GAPDH. It should be noted that DMSO was not needed for the GAPDH analysis.
2.2 Optimization of Electrophoresis
The DMPK was found to separate best when run on a 1% agarose gel for an hour and 20 minutes.
GAPDH, however, only required the length of an hour for electrophoresis. These conditions were kept
standard throughout the experiment.

3. PTM efficiency experiment
3.1 Lipofectamine transfection of PTMs into DM1 cell line
The GM233300 cells were thawed and allowed to grow in RPMI media supplemented with 15% FBS
and 1% penicillin-streptomycin. Cell density was determined by hemocytometer-based counting and
the culture was resuspended at a concentration of 1.2x106 cells per milliliter.
Cells were plated in a 24 well plate. Each well was seeded with 0.5 milliliters of the DM1 cell culture.
Five different conditions were analyzed in triplicate. Two experimental PTMs were used, DMPK and
DMPK AS, alongside the two control PTMs, DMPK Δ3’ss and DMPK AS Δ3’ss and the final condition
contained no PTM. Since each of the four PTM solutions had differing levels of genetic material, serum
free medium was added individually to bring the concentration of each to 1.2 micrograms of DNA per
50 microliters. Following the protocol for lipofectamine transfection, the lipofectamine was diluted with
medium and combined with each of the PTM solution in a 50:50 ratio. After allowing this mixture to
incubate, 100 microliters of each lipofectamine and PTM solution were added to each well, respective
of their identity. Cells were then incubated for 24 hours at 37 C.
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3.2 RNA extraction and PCR assembly
Following incubation, the cells in each well were removed. After pelleting by centrifugation, the cells
were lysed using QIAshredder and RNA extracted using RNeasy mini kit. The extracted RNA was
spectroscopically quantified to determine concentration.
Two RT PCR reactions were assembled for each of the reactions: one using DMPK primers and the
other GAPDH primers. The PCR reactions were mixed and run according to the optimized conditions
listed in Table 4 for the DMPK reaction and Table 5 for the GAPDH reaction. Because of the varying
concentrations of base RNA, the volume added of each was determined so that a total of 100 nanograms
of RNA was added to each reaction. The difference in volume for each was compensated by the addition
of sterile water.

Table 4: RT-PCR DMPK Conditions
5% DMSO Reaction

2x Reaction Mixture
DMPK RT P3
DMPK RT P4
SIII RT
DMSO
RNA
PCR H2O
Total

Quantity (λ)
25
1
1
2
2.5
Volume= 100ng
Adjusted to bring
total volume to 50 λ
50

PCR DMPK Schedule

55 C
94 C
94 C
62.9 C
68 C
68 C
4C

Time
30 minutes
2 minutes
15 seconds
15 seconds
75 seconds
5 minutes
∞

Repeat 39x

Table 5: RT-PCR GAPDH Conditions
Reaction

2x Reaction Mixture
GAPDH rev
GAPDH for
SIII RT
RNA
PCR H2O
Total

Quantity (λ)
25
1
1
2
Volume= 100ng
Adjusted to bring
total volume to 50 λ
50

PCR DMPK Schedule

55 C
94 C
94 C
53.6 C
68 C
68 C

Time
30 minutes
2 minutes
15 seconds
15 seconds
75 seconds
5 minutes

4C

∞

Repeat 39x
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3.3 RNA Analysis
The resulting PCR products were run on the standard 1% agarose gel for the times determined in 2.2.
The samples were run alongside a 100 bp ladder in a 16 well gel. Using GeneSys software, the densities
of each of the bands was determined and each normalized with the results of the GAPDH expression
gel. The ratios between the mutant and the normal DMPK transcripts were compared. The efficiency,
that is, the ratio of normal transcripts to mutant, of each PTM was compared with each other and with
the controls. Figure 6 contains the results of the DMPK gel and the numerical values for each can be
found in table 4.

RESULTS
The gel results showing the mRNA DMPK products for each sample can be seen in Figure 5. From this
gel it can be seen that all the samples displayed a distinct high band and low band corresponding to
mutant DMPK mRNA and wild type/corrected DMPK mRNA as expected. The empty control samples
seemed to show a much less distinct wild type sized product. Table 6, however gives the numerical
results for densities as determined by GeneSys. Figure 6 gives ratio of densities of the high band over
the low band, that is, the number of mutant transcripts per normal transcripts for each experimental
condition after each was standardized by GAPDH expression.
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Table 6: Results- DMPK RT-PCR product band density evaluation
DMPK
~1100bp ~500 bp
Hi
Lo
(Mutant) (correct)

GAPDH

DMPK/GAPDH
Hi/Lo
Hi

Average

Standard
Deviation

Lo

1.1
1.2
1.3

218.1097
142.5281
166.5916

146.62
992.3121
125.2107 1093.682
167.3189 1116.483

0.219799
0.13032
0.149211

0.147756 1.487585
0.114485 1.138306
0.149862 0.995653

1.207181

0.253095

2.1
2.2
2.3

112.2278
211.6267
139.2424

154.0862 170.0726
97.63383 1345.464
144.4144 1273.33

0.659882
0.157289
0.109353

0.906002 0.728344
0.072565 2.167555
0.113415 0.964186

1.286695

0.771907

3.1
3.2
3.3

139.653
183.4277
104.6203

62.85316 1257.736
135.4922 1157.47
97.05919 1877.922

0.111035
0.158473
0.055711

0.049973 2.221893
0.117059 1.353788
0.051684 1.077902

1.551194

0.596997

4.1
4.2
4.3

323.1386
127.285
227.469

91.56604 1162.54
69.72279 1119.243
74.42402 1075.686

0.277959
0.113724
0.211464

0.078764 3.529022
0.062295 1.825587
0.069187 3.056392

2.803667

0.879389

5.1
5.2
5.3

44.55943
306.2594
196.0608

17.83333 1004.617
57.71995 914.3212
18.79845 837.5276

0.044355
0.334958
0.234095

0.017751 2.49866
0.063129 5.305954
0.022445 10.42963

6.07808

4.021466

Key:

1) DMPK

2) DMPK AS 3) DMPK Δ3’ss

4) DMPK AS Δ3’ss

5) Control
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DISCUSSION
A visual analysis of the results as seen in figure 6 may at first glance present a confusing picture.
Initially, it gives the indication that the ratio of mutant to normal transcripts was greater in the overall
control, and that the presence of PTMs regardless of their splicing capabilities seemed to decrease the
amount of toxic transcripts. The wide error bars seen in the graph, however, give an indication that the
numerical results might be lacking in significance ANOVA and post hoc test analysis confirmed the
fact that the gathered data showed not statistical difference between any of the five experimental groups.
The results, therefore show no difference in mutant and normal DMPK transcripts between the cells
containing either type of PTM and the three controls.
The lack of difference between the groups can be interpreted in two ways: either no trans-splicing repair
of DMPK occurred within the model or the trans-splicing repair of DMPK was too minimal to detect.
Taking the first interpretation to be true, one is left to answer why no SMaRT repair occurred. Some
possible scenarios include: 1) the PTM never reached the nucleus 2) the PTM never reached the target
transcription factory.
The possibility of the PTM failing to reach the nucleus the least likely cause. Both lipofectamine, the
transfection regent used for introduction of the PTM into the cell, and the pc3.1DNA vector used to
transport the PTM sequence are standard laboratory tools. Because of these facts, the chance that the
PTM plasmid failed to reach the nucleus is fairly slim and does not provide a reasonable account of the
results. All the same, the possibility that some contaminant may have destroyed the PTM culture or that
the PTMs were degraded in the process of storage is always a lingering possibility, albeit unlikely.
A more worthwhile postulate is that no trans-splicing occurred due to failure of the PTM to be included
in the transcription factory containing the DMPK gene. The failing of PTMs to find their proper position
in the transcription factory has been discussed before. In this case, it is not likely to be wholly due to
faulty binding domain. PTMs of the same construction as the experimental antisense PTMs have been
used successfully in the past. If the problem was due to the binding domain, it would be expected that
at least a small level of splicing would have been observed in the culture receiving the DMPK AS
plasmid. However, neither experimental culture showed splicing. This seems to indicate that the
targeting provided by the binding domain did not play a role in where the experimental PTMs were
positioned within the nucleus.
In this experiment, a fairly high concentration of plasmids was used, 1.2 micrograms per 600,000 cells.
This over dosage of plasmids had been intentional to ensure that PTMs would successfully reach all of
the cells. However, how the number of plasmids affects the sorting processes of the nucleus is not well
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known. It is possible that only plasmids under a certain concentration will be integrated into endogenous
transcription factories. If that concentration is exceeded, it is possible that the nuclear mechanisms
instead associate the plasmids with each other resulting in the creation of an artificial transcription
factory. The high quantity of PTM plasmids within the nucleus of the experimental cultures may have
resulted in them being sequestered into specialized plasmid foci, rather than integrating them into the
DMPK transcription factory. The result of such would be that no splicing would occur and no change
would be seen in the number of mutant DMPK transcripts when compared to their normal companions,
a result that matches the experimental data.
It is additionally worth considering the possibility that trans-splicing of mutant DMPK did occur, but at
low enough levels that the event was undetected. This points to a slight disadvantage of the current
method of data evaluation. Because DMPK transcripts are evaluated by length, the presence of the
normal allele prevents direct detection of trans-spliced products. The failure to differentiate between the
two transcripts is a drawback that should be remedied in future investigations and is required for
understanding what errors are occurring within the experiment.
Though the results of this experiment failed to address the hypothesis and to determine whether the
efficiency SMaRT technology could be improved by a use of a sense binding domain in the PTM, it has
provided valuable ground work for future investigations. Further work should focus on two aspects:
improving differentiation between normal and trans-spliced DMPK transcripts and evaluation of the
effects of plasmid density upon PTM incorporation and segregation within the nucleus.
One method that would allow distinction to be made between normal and repaired DMPK transcripts
would be to include a unique sequence within the coding region of the PTM which would allow the
isolated detection of trans-spliced products. This has the drawback of potentially requiring two PCR
reactions to be run, one looking at endogenous transcripts and the other at repaired products. A different
approach could be prepare the PTM to contain a repeat sequence that was of intermediate length, perhaps
containing 50-100 additional repeats. The same technique of analysis presented in this experiment might
be used. The result would be that instead of two bands as observed, three bands should occur: the high
band for the toxic transcripts, the low band for the endogenous normal transcripts, and an additional
third band somewhere between the two for trans-spliced products. The advantages of such an approach
would be that it would allow a direct visualization of all types of DMPK mRNA present within the cell.
This method would, however, necessitate that the separation of the three bands to be clear enough for
analysis, something that was slightly challenging even when working with two expected bands.
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Additionally, future studies should use lower concentrations of plasmids when transfecting cells. To
determine whether the splicing is affected by concentration, experiments should be conducted using
antisense binding domain plasmids since these have prior experimental evidence of trans-splicing repair.
As the concentration of the PTMs is decreased, the trans-splicing rates should increase. This will allow
the determination of the most favorable plasmid concentration to be used for further experimentation.
Once the plasmid concentration has been optimized, it will be possible to examine the effects on
efficiency that are caused by the use of PTMs with sense binding domain.
SMaRT technology holds great promise in the field of gene therapy, specifically in its potential for
correcting RNA toxicity diseases such as DM1. Demonstrating its potential, however, still requires
much further investigation, particularly in improving the efficiency of the artificial PTM molecules.
Though this study was unable to provide proof of concept for the use of sense binding domains, it has
been an integral part of the future studies that must be done in order to make SMaRT repair of DM1 a
reality. This research has shown the direction that future experimentation ought to take and has set the
foundation for further investigation in binding domain improvement.
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